Pharmaceuticals company Supriya Lifescience announced Q1FY25 results: In the first quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 21.7 % YoY increase, reaching Rs 160.63 crore compared to Rs 132.02 crore in Q1 FY24. EBITDA for Q1 FY25 stood at Rs 62.54 crore, with an EBITDA Margin of 38.9%, as opposed to an EBITDA of Rs 44.49 crore in Q1 FY24 with an EBITDA margin of 33.7%. This marks a growth of 40.6% YoY. The Profit After Tax (PAT) for Q1 FY25 came at Rs 44.64 crore, compared to Rs 28.51 crore in Q1 FY24. The PAT Margin stood at 27.8% in Q1 FY25, compared to 21.6% in Q1 FY24. The company has seen good growth across different therapeutic areas in Q1FY25 European markets now contribute 51% of our business revenue up from 43% in Q4FY24 and 34% in Q1FY24. Saloni Wagh, Managing Director, Supriya Lifescience, commenting on the results, said, “We are engaged in discussions with a diverse range of companies, from major pharmaceutical firms to innovative enterprises, to establish partnerships for supplying tailored products. The company achieved a record capital expenditure of Rs 146 crore in the last financial year while also enhancing its return on equity by 210 basis points. We're proud to unveil our new R&D; facility at Lote Parshuram and anticipate the completion of our Ambernath lab by early Q2FY25. These state-of-the-art centers will drive our next phase of growth, focusing on advanced product development, CMO/CDMO opportunities, and expanding our portfolio to meet evolving market needs. Moving forward, the company aims for significant growth with improved profitability.” Result PDF